Download PDF
Klin Monbl Augenheilkd 2012; 229(5): 534-539
DOI: 10.1055/s-0031-1299530
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Okuläre Beteiligung bei Stevens-Johnson-Syndrom und Toxisch epidermaler Nekrolyse

Ocular Involvement in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
A. Chronopoulos
1   Klinik für Augenheilkunde, Universitätsmedizin, Charité Berlin
,
U. Pleyer
2   Universitäts-Augenklinik, Charité Campus Virchow-Klinik
,
M. Mockenhaupt
3   Dokumentationszentrum schwerer Hautreaktionen (dZh), Universitäts-Hautklinik Freiburg
› Author Affiliations
Further Information

Publication History

27 January 2012

30 March 2012

Publication Date:
16 May 2012 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Das Stevens-Johnson-Syndrom (SJS) und die Toxisch epidermale Nekrolyse (TEN) stellen seltene schwere Reaktionen der Haut- und der Schleimhäute dar. Sie werden als eine Krankheitsentität verschieden schwerer Ausprägung angesehen und werden meist durch Arzneimittel ausgelöst, seltener durch Infekte. Okuläre Komplikationen entwickeln sich bei mehr als 50 % der Betroffenen und sie können unter Umständen ohne rechtzeitige ophthalmologische Intervention zur Erblindung führen. Der akute Befund, der ungewisse Verlauf sowie die extreme Variation und zeitliche Folge der Komplikationen von SJS und TEN erfordern eine interdisziplinäre Behandlung. Rechtzeitige Diagnosestellung und frühzeitige Einleitung einer oberflächenpflegenden anti-inflammatorischen Therapie sind von entscheidender Bedeutung für den weiteren Verlauf und können die Lebensqualität quoad visum erheblich verbessern. Dieser Beitrag soll dem besseren Verständnis dieser Reaktionsformen dienen und so zu einer Verbesserung der visuellen Rehabilitation und Lebensqualität der Patienten führen

Abstract

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare severe reactions of skin and mucous membranes. They are considered as a single disease entity with differing severities and are mainly induced by drugs, less frequently by infections. In 50 % of the patients ocular complications occur, which can lead to blindness in the absence of immediate ophthalmological treatment. The acute pattern, the unpredictable course and extreme variations in the manifestation of complications require an interdisciplinary treatment. Early diagnosis and initiation of an intensive lubricating and anti-inflammatory surface care are of utmost importance for the best visual outcome. This article is intended to help ophthalmologists towards a better understanding and interpretation of clinical signs of these conditions with the goal to achieve substantial improvements in visual outcome and of course the patient’s quality of life

Schlüsselwörter

Kornea - Bindehaut - Pathologie - Stevens-Johnson-Syndrom - Toxisch epidermale Nekrolyse - okuläre Beteiligung

Key words

cornea - conjunctiva - pathology - Stevens-Johnson syndrome - toxic epidermal necrolysis - ocular manifestation
 

  • Literatur

  • 1 Bastuji-Garin S, Rzany B, Stern RS et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92-96
    CrossrefPubMedGoogle Scholar
  • 2 Auquier-Dunant A, Mockenhaupt M, Naldi L et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002; 138: 1019-1024
    CrossrefPubMedGoogle Scholar
  • 3 Rzany B, Hering O, Mockenhaupt M et al. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 1996; 135: 6-11
    CrossrefPubMedGoogle Scholar
  • 4 Rzany B, Mockenhaupt M, Baur S et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990–1992): structure and results of a population-based registry. J Clin Epidemiol 1996; 49: 769-773
    CrossrefPubMedGoogle Scholar
  • 5 Mockenhaupt M, Liß Y. Schwere arzneimittelinduzierte Hautreaktionen: Stevens-Johnson-Syndrom und Toxisch epidermale Nekrolyse. Allergo J 2011; 4: 200-210
    PubMedGoogle Scholar
  • 6 Edward J, Holland DRH. Ocular Infection and Immunity. [by Jay S. Pepose, Gary N. Holland and Kirk R.] St. Louis: Mosby: Wilhelmus; 1996
    Google Scholar
  • 7 Chang YS, Huang FC, Tseng SH et al. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea 2007; 26: 123-129
    CrossrefPubMedGoogle Scholar
  • 8 Power WJ, Ghoraishi M, Merayo-Lloves J et al. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology 1995; 102: 1669-1676
    PubMedGoogle Scholar
  • 9 Mockenhaupt M, Viboud C, Dunant A et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128: 35-44
    CrossrefPubMedGoogle Scholar
  • 10 Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol 2011; 7: 803-813 ; quiz 814 – 805
    CrossrefPubMedGoogle Scholar
  • 11 Chung WH, Hung SI, Yang JY et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008; 14(12): 1343-1350
    CrossrefPubMedGoogle Scholar
  • 12 Roujeau JC, Huynh TN, Bracq C et al. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol 1987; 123: 1171-1173
    CrossrefPubMedGoogle Scholar
  • 13 Lonjou C, Thomas L, Borot N et al. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J 2006; 6: 265-268
    PubMedGoogle Scholar
  • 14 Lonjou C, Borot N, Sekula P et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008; 18: 99-107
    CrossrefPubMedGoogle Scholar
  • 15 Kauppinen K. Cutaneous reactions to drugs with special reference to severe bullous mucocutaneous eruptions and sulphonamides. Acta Derm Venereol Suppl (Stockh) 1972; 68: 1-89
    PubMedGoogle Scholar
  • 16 Foster CS, Fong LP, Azar D et al. Episodic conjunctival inflammation after Stevens-Johnson syndrome. Ophthalmology 1988; 95: 453-462
    PubMedGoogle Scholar
  • 17 Tugal-Tutkun I, Akova YA, Foster CS. Penetrating keratoplasty in cicatrizing conjunctival diseases. Ophthalmology 1995; 102: 576-585
    CrossrefPubMedGoogle Scholar
  • 18 Sotozono C, Ang LP, Koizumi N et al. New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome. Ophthalmology 2007; 114: 1294-1302
    CrossrefPubMedGoogle Scholar
  • 19 Thiel HJ, Richter U, Pleyer U et al. [Drug-induced exudative erythema multiforme major with a chronic progressive course and bilateral blindness. Clinical and immunohistologic follow-up]. Klin Monbl Augenheilkd 1990; 197: 142-149
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 De Rojas MV, Dart JK, Saw VP. The natural history of Stevens Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy. Br J Ophthalmol 2007; 91: 1048-1053
    CrossrefPubMedGoogle Scholar
  • 21 Kuper K, Pleyer U, Zierhut M et al. [Erythema exsudativum multiforme major]. Ophthalmologe 1995; 92: 823-828
    PubMedGoogle Scholar
  • 22 Mukasa Y, Craven N. Management of toxic epidermal necrolysis and related syndromes. Postgrad Med J 2008; 84: 60-65
    CrossrefPubMedGoogle Scholar
  • 23 Furrer P, Mayer JM, Gurny R. Ocular tolerance of preservatives and alternatives. Eur J Pharm Biopharm 2002; 53: 263-280
    CrossrefPubMedGoogle Scholar
  • 24 Quinto GG, Campos M, Behrens A. Autologous serum for ocular surface diseases. Arq Bras Oftalmol 2008; 71: 47-54
    CrossrefPubMedGoogle Scholar
  • 25 Schneck J, Fagot JP, Sekula P et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008; 58: 33-40
    CrossrefPubMedGoogle Scholar
  • 26 Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-493
    CrossrefPubMedGoogle Scholar
  • 27 Faye O, Roujeau JC. Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date. Drugs 2005; 65: 2085-2090
    CrossrefPubMedGoogle Scholar
  • 28 Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003; 139: 33-36
    CrossrefPubMedGoogle Scholar
  • 29 Bastuji-Garin S, Fouchard N, Bertocchi M et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149-153
    CrossrefPubMedGoogle Scholar
  • 30 Wolkenstein P, Latarjet J, Roujeau JC et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352: 1586-1589
    CrossrefPubMedGoogle Scholar
  • 31 Struck MF, Hilbert P, Mockenhaupt M et al. Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes. Intensive Care Med 36: 22-32
    PubMedGoogle Scholar
  • 32 Roujeau JC, Chosidow O, Saiag P et al. Toxic epidermal necrolysis (Lyell’s syndrome). J Am Acad Dermatol 1990; 23: 1039-1058
    CrossrefPubMedGoogle Scholar
  • 33 Koizumi N, Inatomi T, Suzuki T et al. Cultivated corneal epithelial stem cell transplantation in ocular surface disorders. Ophthalmology 2001; 108: 1569-1574
    CrossrefPubMedGoogle Scholar
  • 34 Giasson CJ, Bouchard C, Boisjoly H et al. [Amnion and ocular surface problems]. Med Sci (Paris) 2006; 22: 639-644
    PubMedGoogle Scholar
  • 35 Shay E, Kheirkhah A, Liang L et al. Amniotic membrane transplantation as a new therapy for the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis. Surv Ophthalmol 2009; 54: 686-696
    CrossrefPubMedGoogle Scholar
  • 36 Dua HS, Azuara-Blanco A. Allo-limbal transplantation in patients with limbal stem cell deficiency. Br J Ophthalmol 1999; 83: 414-419
    CrossrefPubMedGoogle Scholar
  • 37 Liu J, Sheha H, Fu Y et al. Oral mucosal graft with amniotic membrane transplantation for total limbal stem cell deficiency. Am J Ophthalmol 152: 739-747 e731
    PubMedGoogle Scholar
  • 38 Romero-Rangel T, Stavrou P, Cotter J et al. Gas-permeable scleral contact lens therapy in ocular surface disease. Am J Ophthalmol 2000; 130: 25-32
    CrossrefPubMedGoogle Scholar
  • 39 Gungor I, Schor K, Rosenthal P et al. The Boston Scleral Lens in the treatment of pediatric patients. J AAPOS 2008; 12: 263-267
    PubMedGoogle Scholar
  • 40 Tougeron-Brousseau B, Delcampe A, Gueudry J et al. Vision-related function after scleral lens fitting in ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Ophthalmol 2009; 148: 852-859 e852
    CrossrefPubMedGoogle Scholar
  • 41 Liu C, Okera S, Tandon R et al. Visual rehabilitation in end-stage inflammatory ocular surface disease with the osteo-odonto-keratoprosthesis: results from the UK. Br J Ophthalmol 2008; 92: 1211-1217
    CrossrefPubMedGoogle Scholar